POSTSCRIPT

Correspondence

New challenges for informed consent through whole genome array testing

C Netzer^1,2, C Klein³, J Kohlhase⁴, C Kubisch^1,2

¹ Institute of Human Genetics, University of Cologne, Germany
² Center of Molecular Medicine Cologne, University of Cologne, Germany
³ Department of Neurology, University of Lübeck, Germany
⁴ Center for Human Genetics Freiburg, Freiburg, Germany

Correspondence to:
Dr C Netzer, Institut für Humangenetik, Uniklinik Köln, Kerpener Str. 34, 50931 Köln, Germany; christian.netzer@uk-koeln.de

The first 150 words of the full text of this article appear below.

We read with great interest the article by Schwarzbraun et al on predictive diagnosis of Li–Fraumeni syndrome established as an accidental finding in whole genome array testing, originally performed to identify the molecular cause of mental retardation (MR) in a 7-year-old child.¹ We would like to expand the spectrum of unexpected and unintended findings with this new technique. In a 5-year-old Kurdish boy with MR and normal karyotype, array comparative genomic hybridisation (CGH) with an Agilent platform (using the Human Genome CGH 244A Microarray Kit with a medium spatial resolution of 12 kb and a threshold of five consecutive aberrant clones) identified a heterozygous intragenic deletion spanning exons 4 and 5 of the Parkin gene (PARK2) as the only significant change (minimal deletion boundaries for NCBI Build 36, chromosome 6: 162,339,755–162,582,128). Bi-allelic mutations of Parkin cause early onset parkinsonism (OMIM 600116 [OMIM] ), a neurodegenerative disorder without phenotypic . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?